Management of hypertension and screening of renal complications by GPs in diabetic type 2 patients (France-2001)

被引:16
作者
Fagnani, F
Souchet, T
Labed, D
Gaugris, S
Hannedouche, T
Grimaldi, A
机构
[1] CHU Pitie Salpetriere, Diabetol Dept, Paris, France
[2] Hop Univ Strasbourg, Dept Nephrol, Strasbourg, France
[3] IMS Hlth, Nanterre, France
[4] Merck Sharp & Dohme Ltd, Chibret, Paris, France
关键词
hypertension; nephropathy; type; 2; diabetes; France; epidemiology;
D O I
10.1016/S1262-3636(07)70008-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Our aim was to assess the quality of the medical management by GPs of hypertension and renal insufficiency in type 2 diabetic patients. Methods: A retrospective cohort study was run on a national random representative sample of 5,518 patients presenting with type 2 diabetes mellitus treated pharmacologically by a general practitioner from April 2000 to April 2001. Results: Sixty percent of patients underwent a HbA(1c) measurement during the last 6 months and among them 27% exceeded the threshold of 8%. Glomerular Filtration Rate, calculated with the Cockcroft formula, was below 60 ml/min (confirmed renal failure) in 21.9% of patients and was in the 61-80 ml/min range (probable early renal insufficiency) in 27%. Proteinuria was documented in 30.1% of patients, 13.7% of whom were positive. Microalbuminuria was documented in 36%, 15% of whom were positive. Hypertension was treated pharmacologically in 59.6% of the sample (39.3% on monotherapy, 34.2% on double combination therapy and 26.5% on triple combination therapy or more). Blood pressure was >140 and/or 80 mmHg in 81.6% of treated patients and in 27% among untreated. Conclusion: These findings suggest that significant progress still needs to be made in the care and treatment of type 2 diabetic patients, especially those with hypertension, in order to reduce or delay the incidence of renal and cardiovascular complications.
引用
收藏
页码:58 / 64
页数:7
相关论文
共 20 条
[1]  
*AG NAT ACCR EV SA, 1999, DIABETES METAB, V2, P35
[2]  
*AG NAT ACCR EV SA, 2000, PRIS CHARG PAT AD AT
[3]   SIMILAR RATE OF PROGRESSION IN THE PREDIALYSIS PHASE IN TYPE-I AND TYPE-II DIABETES-MELLITUS [J].
BIESENBACH, G ;
JANKO, O ;
ZAZGORNIK, J .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1994, 9 (08) :1097-1102
[4]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[5]  
Chantrel F, 2000, DIABETES METAB, V26, P37
[6]  
Detournay B, 1999, DIABETES METAB, V25, P356
[7]  
Detournay B, 2000, DIABETES METAB, V26, P363
[8]  
Halimi S, 1999, DIABETES METAB, V25, P507
[9]   Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:: principal results of the hypertension optimal treatment (HOT) randomised trial [J].
Hansson, L ;
Zanchetti, A ;
Carruthers, SG ;
Dahlöf, B ;
Elmfeldt, D ;
Julius, S ;
Ménard, J ;
Rahn, KH ;
Wedel, H ;
Westerling, S .
LANCET, 1998, 351 (9118) :1755-1762
[10]   Renal disease and hypertension in non-insulin-dependent diabetes mellitus [J].
Ismail, N ;
Becker, B ;
Strzelczyk, P ;
Ritz, E .
KIDNEY INTERNATIONAL, 1999, 55 (01) :1-28